{
  "ticker": "1AD",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971728",
  "id": "02971728",
  "pages": 10,
  "price_sensitive": true,
  "date": "20250723",
  "time": "0849",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250723/pdf/06m1nrs5xz6ynr.pdf",
  "summary": "### **Key Material Information from AdAlta Limited Quarterly Report (June 2025)**  \n\n#### **Capital Raising & Financials**  \n- **Entitlement Offer**: Raised **$1.3M** (before costs) at **$0.003/share**, with 428.1M new shares and 227M options (exercise price: $0.01, expiry: June 2028).  \n- **Cash Balance**: **$1.31M** (up from $0.83M in March 2025).  \n- **Operating Cash Outflow**: **$757k** (down 37% QoQ) due to cost-cutting (staff reduced, R&D paused).  \n- **Funding Runway**: **1.7 quarters** based on current cash and operating burn.  \n\n#### **Strategic Highlights**  \n1. **\"East-to-West\" Strategy**:  \n   - Prioritized **two CAR-T cell therapy assets** for solid cancers (lung, colorectal, ovarian) with clinical data showing efficacy.  \n   - Targeting **licensing deals** by September 2025; one transaction expected to finalize.  \n   - Terminated discussions on a third asset after investor feedback.  \n\n2. **Asset Monetization**:  \n   - **AD-214** (anti-fibrotic drug): New licensing interest from BIO25 conference.  \n   - **WD-34** (anti-malaria i-body\u00ae): Seeking funding for preclinical studies.  \n\n#### **Corporate Updates**  \n- **Cost-Cutting**: Staff reductions, suspended Board/CEO salaries, sold lab equipment ($110k proceeds).  \n- **Debt**: **$447k loan** (15% interest) due November 2025, secured against R&D tax rebate.  \n\n### **Appendix 4C (Cash Flow) Summary**  \n- **Net Operating Cash Flow**: **-$759k** (improved from prior quarter).  \n- **Investing Activities**: **+$110k** (equipment sale).  \n- **Financing Activities**: **+$1.13M** (Entitlement Offer proceeds net of costs).  \n\n---  \n**Actionable Takeaway**: Liquidity remains tight (1.7 quarters runway), but progress on licensing deals could extend viability. Monitor September 2025 for transaction closure.",
  "usage": {
    "prompt_tokens": 6804,
    "completion_tokens": 479,
    "total_tokens": 7283,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-22T23:14:27.675868"
}